Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

Recs

1
Player Avatar zzlangerhans (99.81) Submitted: 7/10/2012 8:20:00 PM : Underperform Start Price: $1.94 NVAX Score: +10.52

Yet another on the long list of biopharmas enjoying an unjustified summer breakout. Trying to follow Novavax's vaccine pipeline gives me motion sickness. For five years I've tried to keep track of neverending phase I and I/II trials that seem to trail off into oblivion and then regenerate themselves months or years later. Nothing much is new of late except a 12M dilutive financing in May, but the stock is nevertheless up 50% from steady state since the beginning of June. Who gave the green light for all these stocks to go up without any rationale, and why wasn't I informed?

Report this Post 2 Replies
Member Avatar KarlMotFool (< 20) Submitted: 7/15/2012 1:55:37 PM
Recs: 0

LOL, a lot of people were left-behind when Novavax's share price started to climb. The many Phase 1 and Phase 1-2 clinical trials are for good reason, such as testing certain adjuvants, testing a trivalent version of the seasonal vaccine and I think they may have tested vaccines from their 1,000 liter bio-reactor. You might want to research Novavax's ability to produce vaccines from a 1,000 liter bio-reactor instead of the initially used 100 liter reactor. A question is if that is a major milestone for going commercial?

The results from Novavax's recent clinical trials is the reason for the recent rise in the share price. Check the results of the RSV Phase1 and you might be impressed (as were some who recently bought into Novavax). You can find the results posted on Novavax's website.

Results of another clinical trial is expected Q3 of this year: any time.

Member Avatar zzlangerhans (99.81) Submitted: 7/16/2012 1:29:00 PM
Recs: 0

Probably the same people who were left behind when Novavax's share price steadily fell over the last year.

Featured Broker Partners


Advertisement